NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

腎上腺素自動注射器

Epinephrine Auto-injector

出版商 Global Industry Analysts, Inc. 商品編碼 938946
出版日期 內容資訊 英文 176 Pages
商品交期: 最快1-2個工作天內
價格
腎上腺素自動注射器 Epinephrine Auto-injector
出版日期: 2021年04月01日內容資訊: 英文 176 Pages
簡介

在COVID-19造成的危機和即將到來的經濟不景氣下,全球腎上腺素自動注射器市場在預測期間內將以5.6%成長。注射液0.15gm區隔預計將成長6%以上,預計在預測期間末達到19億美元。在新方案中,美國的年複合成長率已修改為6.6%。日本的注射液0.15gm區隔,預計在預測期間末達到1億3120萬美元。

本報告提供全球腎上腺素自動注射器市場相關調查,市場概要,COVID-19帶來的影響,各地區、國家的分析與預測,及主要企業的簡介等系統性資訊。

第1部分 簡介、調查手法、調查範圍

第2部分 摘要整理

第1章 市場概要

  • 全球競爭企業的市場佔有率
  • 競爭企業的市場佔有率方案
  • Covid-19的影響和即將到來的全球經濟不景氣

第2章 主要企業

第3章 市場趨勢、促進因素

第4章 全球市場預測

第3部分 市場分析

  • 各地區市場分析
  • 美國
    • 市場資料
    • 美國的腎上腺素自動注射器的市場佔有率,各企業
    • 市場分析
  • 加拿大
  • 日本
  • 中國
  • 歐洲
    • 市場資料
    • 競爭企業的市場佔有率方案
    • 市場分析
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 其他

第4部分 競爭

  • 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP11840

Abstract:

Global Epinephrine Auto-injector Market to Reach $2.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Epinephrine Auto-injector estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027. 0.15gm Dosage, one of the segments analyzed in the report, is projected to record a 6% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the 0.30gm Dosage segment is readjusted to a revised 5.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $535 Million, While China is Forecast to Grow at 5.2% CAGR

The Epinephrine Auto-injector market in the U.S. is estimated at US$535 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$467.1 Million by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

0.5gm Dosage Segment to Record 3.5% CAGR

In the global 0.5gm Dosage segment, USA, Canada, Japan, China and Europe will drive the 3.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$108.9 Million in the year 2020 will reach a projected size of US$138.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$304.9 Million by the year 2027.

Select Competitors (Total 44 Featured) -

  • Adamis Pharmaceuticals Corporation
  • ALK-Abello AS
  • Antares Pharma, Inc.
  • Bausch + Lomb UK Ltd- Emerade
  • Hospira, Inc.
  • Impax Laboratories, Inc.
  • Lincoln Medical
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Epinephrine Auto-injector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Epinephrine Auto-injector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Epinephrine Auto-injector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for 0.15gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for 0.15gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for 0.15gm Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for 0.30gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for 0.30gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for 0.30gm Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for 0.5gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for 0.5gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for 0.5gm Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Individuals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 19: USA Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: USA 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 22: USA Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 28: Canada Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Canada Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Canada 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 31: Japan Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: Japan 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 34: Japan Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Japan Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Japan 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 37: China Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: China 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 40: China Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: China Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: China 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 43: Europe Current & Future Analysis for Epinephrine Auto-injector by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe Historic Review for Epinephrine Auto-injector by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Europe 15-Year Perspective for Epinephrine Auto-injector by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 46: Europe Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Europe Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Europe 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 49: Europe Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Europe Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Europe 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 52: France Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 53: France Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 54: France 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 55: France Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: France Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 57: France 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 58: Germany Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Germany Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 60: Germany 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 61: Germany Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Germany Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 63: Germany 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 64: Italy Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Italy Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 66: Italy 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 67: Italy Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Italy Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 69: Italy 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 70: UK Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 71: UK Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 72: UK 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 73: UK Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: UK Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 75: UK 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Rest of Europe Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 78: Rest of Europe 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 79: Rest of Europe Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Rest of Europe Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 81: Rest of Europe 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 82: Asia-Pacific Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Asia-Pacific Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 84: Asia-Pacific 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 85: Asia-Pacific Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Asia-Pacific Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 87: Asia-Pacific 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 88: Rest of World Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of World Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of World 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
    • TABLE 91: Rest of World Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of World Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of World 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44